Add Yahoo as a preferred source to see more of our stories on Google. Edwards Lifesciences said it has secured FDA approval for the first surgical valve replacement designed for patients with ...

UC San Francisco interventional cardiologists and interventional echocardiographers recently performed the health system’s first commercial transcatheter tricuspid valve replacement procedure using ...

IRVINE, Calif.--(BUSINESS WIRE)-- Edwards Lifesciences Corporation (NYSE: EW) today announced the company’s SAPIEN M3 mitral valve replacement system received CE Mark for the transcatheter treatment ...

Edwards Lifesciences has been awarded CE mark for the Sapien M3 mitral valve replacement system. The approval is for the transcatheter treatment of patients with symptomatic (moderate-to-severe or ...

Edwards Lifesciences stock fell Friday, though the medtech company beat Wall Street's top- and bottom-line expectations.

July 23 (Reuters) - Edwards Lifesciences beat analysts' estimates for second-quarter profit and revenue on Thursday, helped by strong demand for its artificial heart valves used in complex cardiac ...